3 Reasons to Buy Gilead Sciences, Inc. Motley Fool Last December, Gilead announced that a late-stage trial for idelalisib was stopped early because patients receiving a combo of idelalisib plus rituximab showed a highly significant improvement in overall survival and progression-free survival. With the ... Standard Review for Gilead's Oncology Candidate - Analyst Blog Gilead's Idelalisib NDA accepted by US FDA for the treatment of refractory ... |
